01039nas a2200313   4500000000100000008004100001260001600042653001000058653001100068653001300079653002900092653001100121653001400132653002300146653001200169653000900181653001400190653001700204100001400221700001600235700001600251700001800267700001300285245006500298300001100363490000600374520033100380022001400711       1988                            d  c1988 Mar 1910aAdult10aBiopsy10aCapsules10aClinical Trials as Topic10aHumans10aIsoniazid10aLeprostatic Agents10aleprosy10aMale10aSerotonin10aTime Factors1 aAntia N H1 aAmbrose E J1 aUpleker M W1 aMahadevan P R1 aMester L00aEffect of deoxyfructoserotonin (DFS) on lepromatous leprosy.  a619-220 v13 a<p>To examine the anti-leprosy effect of deoxyfructoserotonin the drug was given in a dose of 10 mg/kg for 6 months to 6 patients with active lepromatous leprosy, in accordance with the WHO-THELEP protocol. Clinical and histological assessment and mouse foot-pad studies suggest that the drug has some anti-leprosy effect.</p>  a0140-6736